The U.S. Food and Drug Administration (FDA) panel voted 11-0 that the benefits of Eli Lilly's Alzheimer's drug outweighed the risks.

Disclaimer:

1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.

2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.